Previous close | 1.4680 |
Open | 0.0000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | 21,015 |
Market cap | 27.038M |
Beta (5Y monthly) | 2.62 |
PE ratio (TTM) | N/A |
EPS (TTM) | -7.8050 |
Earnings date | 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Immunovia (Nasdaq Stockholm: IMMNOV), the pancreatic cancer diagnostics company, today presented detailed discovery study results for the company's next-generation early detection test for pancreatic cancer at the PancreasFest 2024 Annual Meeting (abstract #P33).
Immunovia (NASDAQ: IMMNOV) (STOCKHOLM: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today offers an update on its new lab in Research Triangle Park, USA.
Today, on 19 June 2024, the annual general meeting of Immunovia AB (publ) was held. A summary of the adopted resolutions follows below.